Paxlovid

The revision is a step toward finalizing the transition from Paxlovid's emergency use authorization to its new drug application label, initiated in late 2023.

Researchers believe they've identified the mechanisms that allow the SARS-CoV-2 virus to be so effective at making us ...

Researchers found little difference in outcomes between Paxlovid users and nonusers. They also found 1 in 5 users ...

Only 2018 featured a higher number of drug approvals.

Many Paxlovid recipients have suffered from renewed symptoms.

Out of the 31 long COVID conditions, Paxlovid was found to minimize the incidence of only one.

Pfizer projects Paxlovid sales to fall by 58 percent this year compared to 2022.

Researchers said that both oral antiviral drugs can be used to treat nonhospitalized patients at high risk of ...

Commentary In a recent interview, Dr. Robert Califf, the commissioner of the Food and Drug Administration, admitted to ...

The Department of Justice has accused a former Pfizer employee and his friend and business partner in participating ...

[FULL TRANSCRIPT BELOW]“With the exception of the medical boards, all the authorities, or all the [organizations] in Brazil, ...

The U.S. Food and Drug Administration (FDA) on May 25 fully approved Pfizer’s oral antiviral medication Paxlovid to ...

An advisory committee from the U.S. Food and Drug Administration (FDA) has voted in favor of approving a ...

The National Institutes of Health (NIH) is conducting a multi-site clinical trial to evaluate Shionogi & Co.’s Xocova ...

Do you know when Paxlovid should be used to treat COVID-19? Are you aware of the reasons for ...

COVID-19 vaccines and treatments that have been free of charge to consumers, due to U.S. government funding, will ...

Doctors and pharmacists can now prescribe COVID-19 drugs Paxlovid and Lagevrio to patients without a positive test of ...

A breakneck pace and a lack of transparency are marking COVID-19's spread to hundreds of millions of people ...

Communication on COVID-19 between top public health officials in Canada and the U.S. has been limited, based on ...

Shanghai continues to be challenged with surging COVID-19 infections. Patients are too numerous to be handled, and the ...

A former White House adviser said the Chinese Communist Party (CCP) is covering the truth of the COVID-19 ...

News Analysis Chinese people are searching for Indian-made generic drugs after Paxlovid, Pfizer’s COVID-19 antiviral drug, was recently ...

Officials in China’s central province of Henan have said that the COVID-19 infection rate in the region was ...

China’s National Healthcare Security Administration (NHSA) announced on Jan. 10 that it will not include Pfizer’s Paxlovid in ...

Satellite images are highlighting China’s death surge, showing an uptick in the number of vehicles parked at funeral ...

The Biden administration and government agencies continue to push Pfizer's COVID-19 emergency use authorization product, Paxlovid, even with insufficient ...

The United States has struck a deal with Pfizer to pay the pharmaceutical giant almost $2 billion for ...